AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19703824 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERdisciplinary COMmunity‐based COPD management programme (INTERCOM)
Number of subjects: 199
Study 19703824 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 199
Study 19022121 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric osteotomy technique
Number of subjects: 100
Study 19022121 — intervention group
Group type: COMPARATOR
Intervention: Rotatory osteotomy technique
Number of subjects: 100
Study 17038243 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nutrition support + Gln 100 ml/d + rhGH 10 U/d (Group C)
Number of subjects: 90
Study 17038243 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition support (Group A)
Number of subjects: 90
Study 17038243 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition support + 10% Gln 100 ml/d (Group B)
Number of subjects: 90
Study 12812018 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine System (TNS) for 3 weeks
Number of subjects: 160
Study 12812018 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine System (TNS) for 6 weeks
Number of subjects: 160
Study 12812018 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 160
Study 12812018 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 160
Study 11157426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 186
Study 11157426 — intervention group
Group type: COMPARATOR
Intervention: Control drugs (tricyclics/heterocyclics and SSRIs)
Number of subjects: 186
Study 9135526 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative external beam radiotherapy (30 Gy in 10 fractions)
Number of subjects: 67
Study 9135526 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 67
Study 8116276 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular viewing of a simulated object with varying speed
Number of subjects: 7
Study 8116276 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular viewing of a simulated object with removed cues
Number of subjects: 7
Study 3299016 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-733 (low dose: 2.5-10 mg/day)
Number of subjects: 30
Study 3299016 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-733 (high dose: 20-80 mg/day)
Number of subjects: 30
Study 3299016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30829057 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir (prophylactic treatment)
Number of subjects: 0
Study 30829057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 28624696 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of trastuzumab and taxane chemotherapy
Number of subjects: 5502
Study 28624696 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of trastuzumab after chemotherapy
Number of subjects: 5502
Study 25933389 — intervention group
Group type: EXPERIMENTAL
Intervention: Original brand placebo (500 mg Aspirin)
Number of subjects: 0
Study 25933389 — intervention group
Group type: COMPARATOR
Intervention: Generic placebo (1A Pharma)
Number of subjects: 0
Study 23057419 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 118
Study 21705493 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of intravenous iron (III)-hydroxide sucrose
Number of subjects: 90
Study 21705493 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 90
Study 18778396 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 75
Study 16957676 — intervention group
Group type: EXPERIMENTAL
Intervention: Estromineral serena (ES) - 1 tablet/day for 24 weeks
Number of subjects: 89
Study 16957676 — intervention group
Group type: COMPARATOR
Intervention: Calcium + Vitamin D3 (Ca+D) - 1 tablet/day for 24 weeks
Number of subjects: 89
Study 16957676 — intervention group
Group type: EXPERIMENTAL
Intervention: Estromineral serena (ES)
Number of subjects: 89
Study 16957676 — intervention group
Group type: COMPARATOR
Intervention: Calcium + Vitamin D3 (Ca+D)
Number of subjects: 89
Study 15077843 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient substance abuse treatment
Number of subjects: 140
Study 11304940 — intervention group
Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg + dienogest 3 mg)
Number of subjects: 49
Study 11304940 — intervention group
Group type: COMPARATOR
Intervention: Climodien (estradiol valerate 2 mg + dienogest 2 mg)
Number of subjects: 49
Study 11304940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 9034258 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin solution (0.6 g/kg) administered after withdrawing 15 mL/kg of blood over 30 mins in group 2.
Number of subjects: 26
Study 9034258 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1) without hemodilution.
Number of subjects: 26
Study 8509529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol plus quinidine
Number of subjects: 50
Study 8509529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol plus procainamide
Number of subjects: 50
Study 8509529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol plus quinidine or procainamide
Number of subjects: 50
Study 8509529 — intervention group
Group type: COMPARATOR
Intervention: Alternative therapy after combination therapy was discontinued
Number of subjects: 50
Study 30943512 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of the primary tumour and lymph nodes metastasis
Number of subjects: 0
Study 30943512 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical approaches (including radiotherapy and systemic medical treatment)
Number of subjects: 0
Study 30943512 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy
Number of subjects: 0
Study 28829248 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual Week test
Number of subjects: 58
Study 27019066 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram infusion
Number of subjects: 8
Study 27019066 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 24440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pelvic floor muscle training (PFMT), three times a day for four weeks, 30 days before RP
Number of subjects: 16
Study 24440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pelvic floor muscle training (PFMT)
Number of subjects: 16
Study 24440083 — intervention group
Group type: COMPARATOR
Intervention: Control Group (routine pre‐surgical education)
Number of subjects: 16
Study 21401720 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG(S)
Number of subjects: 98
Study 20195019 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation training in conjunction with strength-training exercises (PERT group)
Number of subjects: 40
Study 20195019 — intervention group
Group type: COMPARATOR
Intervention: Progressive quadriceps strength-training exercises (STR group)
Number of subjects: 40
Study 16996783 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis combined with pre and postsurgery hyperbaric oxygen (HBO) treatment
Number of subjects: 26
Study 16996783 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 26
Study 16199795 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75‐225 mg/day)
Number of subjects: 361
Study 16199795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 12022898 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (180 mg caffeine in 200 mL beverage)
Number of subjects: 28
Study 12022898 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (3.6 mg caffeine in 200 mL beverage)
Number of subjects: 28
Study 10427296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation programme
Number of subjects: 0
Study 8521744 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg once daily)
Number of subjects: 56
Study 8521744 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin (with or without fusidic acid)
Number of subjects: 56
Study 8521744 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin + fusidic acid
Number of subjects: 56
Study 1968308 — intervention group
Group type: COMPARATOR
Intervention: Dopamine infusion at 0.04, 0.4, and 4.0 micrograms.kg‐1.min‐1
Number of subjects: 30
Study 1968308 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg) after 17 h during dopamine infusion
Number of subjects: 30
Study 1968308 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam (0.5 micrograms.kg‐1.min‐)
Number of subjects: 30
Study 7191311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (180 mg/day)
Number of subjects: 40
Study 7191311 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (150 mg/day)
Number of subjects: 40
Study 30763545 — intervention group
Group type: EXPERIMENTAL
Intervention: My Birth Control (intervention)
Number of subjects: 758
Study 30763545 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 758
Study 30286145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube lubricated with water
Number of subjects: 296
Study 30286145 — intervention group
Group type: COMPARATOR
Intervention: Tube without lubrication
Number of subjects: 296
Study 26555945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (group B)
Number of subjects: 525
Study 26555945 — intervention group
Group type: COMPARATOR
Intervention: Mammalian target of rapamycin inhibitor-free immunosuppression (group A)
Number of subjects: 525
Study 25275972 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 68
Study 25275972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate injection
Number of subjects: 68
Study 22746387 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) monotherapy
Number of subjects: 68
Study 22746387 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) instillations
Number of subjects: 68
Study 22746387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 20194881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 672
Study 20194881 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 672
Study 17403819 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage, irrigation, and fibrinolytic therapy
Number of subjects: 70
Study 17403819 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (tapping of cerebrospinal fluid by reservoir)
Number of subjects: 70
Study 17403819 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 70
Study 15728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Proband-initiated contact strategy; Phase 1: 99 proband enrollment forms; Phase 2: 50 sibling reply cards.
Number of subjects: 99
Study 11985761 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 57
Study 11985761 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 57
Study 9616309 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (3 x 1 mg/day)
Number of subjects: 179
Study 9616309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 8706113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 27
Study 8706113 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT) with clonidine pretreatment
Number of subjects: 27
Study 8706113 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 2558829 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH-low: 3,000 aXa U
Number of subjects: 20
Study 2558829 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH-medium: 4,000 aXa U
Number of subjects: 20
Study 2558829 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH-high: 5,000 aXa U
Number of subjects: 20
Study 2558829 — intervention group
Group type: COMPARATOR
Intervention: UFH regimen: 5,000 IU bolus and 1,500 IU/h infusion
Number of subjects: 20
Study 2558829 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens (including UFH)
Number of subjects: 20
Study 911730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine and phenylephrine drops
Number of subjects: 58
Study 911730 — intervention group
Group type: COMPARATOR
Intervention: Dummy provocative test (Control)
Number of subjects: 58
Study 31944081 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium sulfate at 180 kg ha‐1 K2O
Number of subjects: 3
Study 31944081 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride at 180 kg ha‐1 K2O
Number of subjects: 3
Study 31944081 — intervention group
Group type: COMPARATOR
Intervention: No potassium fertilization
Number of subjects: 3
Study 30700946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet for 16 weeks
Number of subjects: 20
Study 30700946 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet for 16 weeks
Number of subjects: 20
Study 30376755 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Kinesthetic Instruction for Preschoolers (SKIP) intervention (360 min total over 6 weeks, 30-min sessions twice weekly)
Number of subjects: 107
Study 30376755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 107
Study 25931239 — intervention group
Group type: EXPERIMENTAL
Intervention: SWIFT Cast
Number of subjects: 105
Study 25931239 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physical Therapy (CPT)
Number of subjects: 105
Study 25330506 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS‐TAVR for severe aortic regurgitation (AR)
Number of subjects: 26
Study 23250018 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrosphère™ rehabilitation for 9 days
Number of subjects: 24
Study 23250018 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical revalidation for 9 days
Number of subjects: 24
Study 23250018 — intervention group
Group type: COMPARATOR
Intervention: Control group of 20 non-faller subjects aged 79.9
Number of subjects: 24
Study 20303646 — intervention group
Group type: EXPERIMENTAL
Intervention: Second TUR (performed within 2-6 weeks after initial resection)
Number of subjects: 210
Study 20303646 — intervention group
Group type: COMPARATOR
Intervention: No second TUR
Number of subjects: 210
Study 20303646 — intervention group
Group type: EXPERIMENTAL
Intervention: Second TUR
Number of subjects: 210
Study 17321065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal ratio (NR) < or = 0.20
Number of subjects: 544
Study 17321065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal ratio (NR) > or = 0.20
Number of subjects: 544
Study 17321065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal positivity using NR
Number of subjects: 544
Study 17321065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal ratio >0.20
Number of subjects: 544
Study 17321065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analysis
Number of subjects: 544
Study 16863974 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery (MICS) technique
Number of subjects: 80
Study 16863974 — intervention group
Group type: COMPARATOR
Intervention: Standard stop‐and‐chop phacoemulsification
Number of subjects: 80
Study 16863974 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 80
Study 12578926 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 64
Study 12578926 — intervention group
Group type: COMPARATOR
Intervention: Cognitively Normal Older Controls
Number of subjects: 64
Study 12578926 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Alzheimer's Disease (AD)
Number of subjects: 64
Study 10559703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan enhancement (amino acid drink enhanced with tryptophan)
Number of subjects: 28
Study 10559703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (amino acid drink depleted of tryptophan)
Number of subjects: 28
Study 8909663 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg
Number of subjects: 204
Study 8909663 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 204
Study 8909663 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclizine 50 mg
Number of subjects: 204
Study 8909663 — intervention group
Group type: COMPARATOR
Intervention: no antiemetic
Number of subjects: 204
Study 2069491 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (100 mg)
Number of subjects: 22
Study 2069491 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 22
Study 6402162 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing verbal advice with a booklet
Number of subjects: 1550
Study 6402162 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing verbal advice with a booklet and nicotine chewing gum
Number of subjects: 1550
Study 6402162 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing verbal advice with a booklet and placebo chewing gum
Number of subjects: 1550
Study 6402162 — intervention group
Group type: COMPARATOR
Intervention: Verbal advice alone
Number of subjects: 1550
Study 31113442 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel self-management intervention led by health professionals
Number of subjects: 9
Study 31113442 — intervention group
Group type: COMPARATOR
Intervention: Technological supporting tool
Number of subjects: 9
Study 26418434 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 72
Study 26418434 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 72
Study 26418434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 23398452 — intervention group
Group type: EXPERIMENTAL
Intervention: Online ABD learning package consisting of symptom‐based decision‐making pathways underpinned by a ratified ABD evidence‐based guideline
Number of subjects: 248
Study 23398452 — intervention group
Group type: COMPARATOR
Intervention: Online dummy package
Number of subjects: 248
Study 21242788 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial trophic enteral nutrition (10 mL/hr)
Number of subjects: 200
Study 21242788 — intervention group
Group type: COMPARATOR
Intervention: Initial full-energy enteral nutrition
Number of subjects: 200
Study 19526159 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) propofol
Number of subjects: 60
Study 19526159 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) metoclopramide
Number of subjects: 60
Study 19526159 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (Control)
Number of subjects: 60
Study 18001178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation with 1.1 GBq (n = 36) or 3.7 GBq (131)I (n = 58)
Number of subjects: 136
Study 18001178 — intervention group
Group type: COMPARATOR
Intervention: No ablative therapy (n = 42)
Number of subjects: 136
Study 19777723 — intervention group
Group type: EXPERIMENTAL
Intervention: Home chemotherapy
Number of subjects: 0
Study 19777723 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based HPs
Number of subjects: 0
Study 19777723 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based HPs
Number of subjects: 0
Study 19777723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of HPs
Number of subjects: 0
Study 19777723 — intervention group
Group type: EXPERIMENTAL
Intervention: Service delivery issues
Number of subjects: 0
Study 12151468 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 to 3.5 mg per day)
Number of subjects: 101
Study 12151468 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101
Study 12151468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (concomitant injections of M-M-R II, VARIVAX, and TETRAMUNE)
Number of subjects: 609
Study 9849978 — intervention group
Group type: COMPARATOR
Intervention: Group B (VARIVAX given 6 weeks after M-M-R II and TETRAMUNE)
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (VARIVAX injection sites)
Number of subjects: 609
Study 9849978 — intervention group
Group type: COMPARATOR
Intervention: Group B (VARIVAX injection sites)
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (TETRAMUNE sites)
Number of subjects: 609
Study 9849978 — intervention group
Group type: COMPARATOR
Intervention: Group B (TETRAMUNE sites)
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-R II alone
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-R II with VARIVAX
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIVAX alone
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-R II and TETRAMUNE together (Days 0 to 3)
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-R II and TETRAMUNE together (Days 7 to 21)
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIVAX alone (Days 0 to 3)
Number of subjects: 609
Study 9849978 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIVAX alone (Days 7 to 21)
Number of subjects: 609
Study 7507504 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute reperfusion (1,309 patients)
Number of subjects: 1944
Study 7507504 — intervention group
Group type: COMPARATOR
Intervention: No acute reperfusion (635 patients)
Number of subjects: 1944
Study 2681578 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte transfusion
Number of subjects: 16
Study 805050 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg, 3 times daily)
Number of subjects: 47
Study 805050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31686199 — intervention group
Group type: EXPERIMENTAL
Intervention: SNZ TriBac
Number of subjects: 60